Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Pregnancy RelatedProtein S Deficiency
Interventions
DRUG

Enoxaparin

Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.

DRUG

Aspirin

Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.

DRUG

Enoxaparin

Participants in all groups will receive daily injections of enoxaparin at a dose of 4000 IU within 6 weeks at postpartum.

Trial Locations (1)

100010

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Obstetrics and Gynecology Hospital

OTHER

collaborator

Beijing Hospital

OTHER_GOV

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Sichuan Academy of Medical Sciences

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Chinese PLA General Hospital

OTHER

collaborator

Beijing Friendship Hospital

OTHER

collaborator

Beijing Chuiyangliu Hospital

OTHER_GOV

lead

Peking University People's Hospital

OTHER

NCT06531525 - Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency | Biotech Hunter | Biotech Hunter